A Randomized, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SBT115301 in Healthy Participants
Latest Information Update: 01 Oct 2024
At a glance
- Drugs SBT 11 5301 (Primary) ; SBT 11 5301 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Sonoma Biotherapeutics
- 30 Sep 2024 Status changed from active, no longer recruiting to completed.
- 07 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jun 2024.
- 07 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jun 2024.